What Illumina's 8-K filings say: 8 filings, latest Aug 17, 2026
Illumina filed its latest 8-K with the SEC on Aug 17, 2026. It discusses debt refinancing.
Public (ILMN)Biotechnology Research10,000+ employeesillumina.comLinkedIn
- Filed
- Aug 17, 2026
- Filings
- 8
- Signals
- 19
8-K · latest 9
What Illumina's 8-K filings say
- SEC EDGAR
8-K
Filed · 1 signal
Illumina raises $300M in new debt to refinance existing notes maturing in September 2026.
Illumina is issuing new 4.950% notes due 2029 to help repay $500M of existing notes maturing in September 2026.
$300M
Aggregate principal amount of new 4.950% notes due 2029.
4.95%
Interest rate on new notes due 2029.
U.S. Bank Trust Company, National AssociationCravath, Swaine & Moore LLP
- SEC EDGAR
8-K
Filed · 3 signals
Illumina secures new $1B revolving credit facility, enhancing financial flexibility.
The company has entered into a new $1 billion, five-year credit agreement, providing significant capital for working capital and general corporate purposes.
$1B
Senior unsecured five-year revolving credit facility for working capital and general corporate purposes.
Bank of America, N.A.
- SEC EDGAR
8-K
Filed · 1 signal
Illumina to raise $300M in new debt to refinance existing notes due September 2026.
Illumina is issuing $300 million in new 4.950% notes to repay its older 4.650% notes.
$300M
Issuance of 4.950% notes due 2029 to repay existing debt.
J.P. Morgan Securities LLCCitigroup Global Markets Inc.
- SEC EDGAR
8-K
Filed · 1 signal
The company is settling a major shareholder lawsuit to avoid the financial burden and management distraction of continued litigation.
- SEC EDGAR
8-K
Filed · 3 signals
Illumina appoints Dr. Daniel M. Skovronsky to its Board of Directors, expanding board to 10 members.
The appointment of a new, independent board member with a strong M.D.
- SEC EDGAR
8-K
Filed · 3 signals
Three Illumina board members to retire simultaneously in May 2026
The departure of three directors (Frances Arnold, Robert Epstein, Gary Guthart) at the same time can signal a significant shift in board oversight and corporate strategy.
Three Board Directors, Drs. Arnold, Epstein, and Guthart, to retire on May 21, 2026
The simultaneous retirement of three directors creates a significant shift in board composition and oversight.
- SEC EDGAR
8-K
Filed · 4 signals
Illumina completes $350M cash acquisition of Standard BioTools' proteomics business
Illumina has acquired SomaLogic and other entities for $350M cash plus up to $75M in milestones, signaling a major strategic expansion into proteomics.
$350M
Cash purchase price for Standard BioTools' proteomics business
proteomics
- SEC EDGAR
8-K
Filed · 3 signals
Showing 9 of 19 filing signals. The Signal API returns all of them.
Get them with one API callSignal API · MCP
Track Illumina with the Signal API
One POST /v1/companies/enrich call with illumina.com returns Illumina 8-K signals (sec-8k), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"illumina.com","signal_types":["sec-8k"],"limit":20}'Same industry
8-K at related companies
Questions about Illumina 8-K
When did Illumina file its latest 8-K?
What did Illumina disclose in its latest 8-K?
Where can I read Illumina's 8-K filing?
Source. Current reports (Form 8-K) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .